Promore Pharma is granted a patent for PXL01 in the US
STOCKHOLM, November 12, 2019 – Promore Pharma AB, a Swedish biopharmaceutical developer of therapeutic peptides, today announced that its subsidiary Pergamum AB was granted a patent in the US for the pharmaceutical formulation of the product candidate PXL01.Promore Pharma’s subsidiary Pergamum owns the intellectual property rights of PXL01, which initially is being developed to prevent post-surgical adhesions after tendon repair surgery. The U.S. Patent Office (USPTO) issued a Notice of Allowance in June 2019 and the patent, which protects the formulation of PXL01 in combination with high